News

In the study conducted in animal models the drug, E1-INT, was shown to induce the regeneration of islet cells that produce insulin. Two weeks of daily E1-INT treatments

Patients with Pompe disease display a range of symptoms that correspond with the age of disease onset and the rate of disease progression. Progressive weakness in the muscles

The product launch is anticipated in Italy before the end of the year. Risperdal Consta (risperidone) is now approved in more than 70 countries. Janssen-Cilag currently markets the

This is the first molecule to enter clinical testing from Microbia’s cardiovascular research program. The objectives of the phase I program are to evaluate the safety, tolerability, pharmacokinetics,

QSA was until late a subsidiary of AEA Technology. On September 13, 2005 AEA announced plans to sell QSA, along with other assets, to private equity company Coller

The study demonstrated that Epiceram accelerated skin barrier recovery in treated vs untreated eczema sites. This objective measurement in the improvement of skin barrier function correlated to a

The investigation including more than 3,000 patients shows Taxotere, a non-anthracycline-based chemotherapy, combined with Herceptin could improve disease-free survival with no increase of cardiotoxicity in patients with early

The new drug appears to offer pain relief and increased mobility to rheumatoid arthritis patients who have exhausted their other medical treatment options. Dr Mark Genovese, Stanford University

GSK is seeking US approval of Arranon for the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in pediatric and adult patients whose disease has not